In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible gram-negative clinical isolates obtained from patients in Canadian hospitals

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3623-3626

  Denisuik, Andrew J ^a   Karlowsky, James A ^a   Denisuik, Tyler ^a   Nichols, Wright W ^b   Keating, Thomas A ^b,c   Adam, Heather J ^a   Baxter, Melanie ^a   Walkty, Andrew ^a   Zhanela, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ASTRAZENECA   (United Kingdom)

^c IMMUNOGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AVIBACTAM PLUS CEFTAZIDIME; BACTERIAL RNA; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; RNA 16S; RNA METHYLTRANSFERASE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; CROSS RESISTANCE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; GENETICS; HOSPITAL; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CANADA; CEFTAZIDIME; GENTAMICINS; GRAM-NEGATIVE BACTERIA; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; RNA, RIBOSOMAL, 16S;

EID: 84929615655     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00364-15     Document Type: Article

References (20)

1. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace- Wiens PRS, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73:159-177. http://dx.doi.org/10.1007/s40265-013-0013-7.
2. Poulikakos P, Falagas ME. 2013. Aminoglycoside therapy in infectious diseases. Expert Opin Pharmacother 14:1585-1597. http://dx.doi.org/10.1517/14656566.2013.806486.
3. Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. Drug Resist Updat 13:151-171. http://dx.doi.org/10.1016/j.drup.2010.08.003.
4. Vakulenko SB, Mobashery S. 2003. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 16:430-450. http://dx.doi.org/10.1128/CMR.16.3.430-450.2003.
5. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagace-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ, Canadian Antimicrobial Resistance Alliance. 2013. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother 68(Suppl 1):i7-i22. http://dx.doi.org/10.1093/jac/dkt022.
6. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HE. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 54:4636-4642. http://dx.doi.org/10.1128/AAC.00572-10.
8. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66:48-53. http://dx.doi.org/10.1093/jac/dkq408.
9. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Fritsche TR, Castanheira M, Miller GH, Jones RN, Armstrong ES. 2008. Detection of methyltransferases conferring high-level resistance to aminoglycosides in Enterobacteriaceae from Europe, North America, and Latin America. Antimicrob Agents Chemother 52:1843-1845. http://dx.doi.org/10.1128/AAC.01477-07.
11. Wachino JI, Arakawa Y. 2012. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gramnegative bacteria: an update. Drug Resist Updat 15:133-148. http://dx.doi.org/10.1016/j.drup.2012.05.001.
12. Bell JM, Andersson P, Jones R, Turnidge J. 2010. 16S rRNA methylase containing Enterobacteriaceae in the SENTRY Asia-Pacific region frequently harbor plasmid-mediated quinolone resistance and CTX-M types. Clin Microbiol Infect 16(Suppl):S127.
13. Hidalgo L, Hopkins KL, Gutierrez B, Ovejero CM, Shukla S, Douthwaite S, Prasad KN, Woodford N, Gonzalez-Zorn B. 2013. Association of the novel aminoglycoside resistance determinant RmtF with NDM carbapenemase in Enterobacteriaceae isolated in India and the UK. J Antimicrob Chemother 68:1543-1550. http://dx.doi.org/10.1093/jac/dkt078.
14. Levasseur P, Girard AM, Claudon M, Goossens H, Black MT, Coleman K, Miossec C. 2012. In vitro antibacterial activity of the ceftazidime-avibactam (NXL 104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 56:1606-1609. http://dx.doi.org/10.1128/AAC.06064-11.
15. Flamm RK, Stone GG, Sader HS, Jones RN, Nichols WW. 2014. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 26:333-338. http://dx.doi.org/10.1179/1973947813Y.0000000145.
16. Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. 2014. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 58:1684-1692. http://dx.doi.org/10.1128/AAC.02429-13.
17. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34:634-640. http://dx.doi.org/10.1086/338782.
18. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ. 1997. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin Infect Dis 24(Suppl):S46-S62. http://dx.doi.org/10.1093/clinids/24.Supplement-1.S46.
19. Shaw KJ, Rather PN, Hare RS, Miller GH. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57:138-163.
20. Cerexa. 2014. Ceftazidime-avibactam briefing package. Cerexa, Oakland, CA. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM425458.pdf.